Oncolytics Biotech (ONCY) Registration Filing summary

Company overview and business model

• Focuses on research and development of pelareorep, an intravenously delivered immunotherapeutic agent targeting various cancers, with no commercialized products to date.

• Operates through two subsidiaries: Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc.

• Incorporated in Alberta, Canada, and listed on Nasdaq under the symbol “ONCY”; voluntarily delisted from the Toronto Stock Exchange in August 2025.

Financial performance and metrics

• Has not achieved profitability since inception and expects continued substantial losses as R&D continues.

• Financial statements are prepared under IFRS and audited by Ernst & Young LLP, with a going concern warning noted in the latest audit.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be allocated as described in the applicable prospectus supplement for each offering.